KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash from Operations (2016 - 2026)

Neogenomics filings provide 17 years of Cash from Operations readings, the most recent being 8137000.0 for Q1 2026.

  • On a quarterly basis, Cash from Operations rose 67.87% to 8137000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 22420000.0, a 194.57% increase, with the full-year FY2025 number at 5230000.0, down 25.53% from a year prior.
  • Cash from Operations hit 8137000.0 in Q1 2026 for Neogenomics, down from 1343000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 20330000.0 in Q2 2025 to a low of 29040000.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 3685000.0 (2022), compared with a mean of 3754705.88.
  • Biggest five-year swings in Cash from Operations: tumbled 1414.03% in 2022 and later surged 997.42% in 2024.
  • Neogenomics' Cash from Operations stood at 3685000.0 in 2022, then soared by 582.61% to 17784000.0 in 2023, then crashed by 44.89% to 9800000.0 in 2024, then tumbled by 86.3% to 1343000.0 in 2025, then crashed by 705.88% to 8137000.0 in 2026.
  • The last three reported values for Cash from Operations were 8137000.0 (Q1 2026), 1343000.0 (Q4 2025), and 8884000.0 (Q3 2025) per Business Quant data.